The Experts below are selected from a list of 1470 Experts worldwide ranked by ideXlab platform
Luciana Pf Abbade - One of the best experts on this subject based on the ideXlab platform.
-
Gabapentin versus Dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial.
European journal of dermatology : EJD, 2018Co-Authors: Mariele Gobo-oliveira, Vitoria G Pigari, Matheus S. P. Ogata, Hélio Amante Miot, Daniela Ponce, Luciana Pf AbbadeAbstract:Background Uremic pruritus is a common symptom in chronic renal failure patients with undefined pathophysiology. Initial treatment involves topical therapy mainly in the form of moisturizers, however, in many cases, this is not sufficient to relieve itching. Systemic adjuvant therapy is therefore necessary, which commonly includes oral antihistamines, with limited success. Positive effects have been reported for gabapentin. Objectives To evaluate the efficacy and safety of gabapentin vs. Dexchlorpheniramine in reducing uremic pruritus. Materials & methods A randomized, controlled, double-blinded clinical trial for haemodialysis patients with persistent pruritus was performed. Pre-randomisation, cold cream was used for 15 days by 71 participants. Those with pruritus who remained in the study (60 patients) were randomised to receive gabapentin (30 patients; GABA group) or Dexchlorpheniramine (30 patients; DEX group) for 21 days. The primary outcome was the decrease in pruritus score and improvement in quality of life. Results After cold cream use, the participants demonstrated a 37.5% median reduction in Visual Analogue Scale (p 0.7). The median DLQI was reduced from 2 to 1 in the GABA group and from 2 to 0 in the DEX group. Nineteen patients (32%) reported mild/moderate side effects without differences between the groups. Conclusions Uremic pruritus was reduced upon treatment with gabapentin or Dexchlorpheniramine with good safety profiles; no difference was observed between the two treatments.
-
Gabapentin versus Dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
European Journal of Dermatology, 2018Co-Authors: Mariele Gobo-oliveira, Vitoria G Pigari, Matheus S. P. Ogata, Hélio Amante Miot, Daniela Ponce, Luciana Pf AbbadeAbstract:Background Uremic pruritus is acommonsymptom in chronic renal failure patients with undefined pathophysiology. Initial treatment involves topical therapy mainly in the form of moisturizers, however, in many cases, this is not sufficient to relieve itching. Systemic adjuvant therapy is therefore necessary, which commonly includes oral antihistamines, with limited success. Positive effects have been reported for gabapentin. Objectives To evaluate the efficacy and safety of gabapentin vs. Dexchlorpheniramine in reducing uremic pruritus. Materials & Methods A randomized, controlled, double-blinded clinical trial for haemodialysis patients with persistent pruritus was performed. Pre-randomisation, cold cream was used for 15 days by 71 participants. Those with pruritus who remained in the study (60 patients) were randomised to receive gabapentin (30 patients; GABA group) or Dexchlorpheniramine (30 patients;DEXgroup) for 21 days. The primary outcomewas the decrease in pruritus score and improvement in quality of life. Results After cold cream use, the participants demonstrated a 37.5% median reduction in Visual Analogue Scale ( p
Ritva Karinen - One of the best experts on this subject based on the ideXlab platform.
-
determination of acetaminophen Dexchlorpheniramine caffeine cotinine and salicylic acid in 100 μl of whole blood by uhplc ms ms
Journal of Analytical Toxicology, 2018Co-Authors: Maja Krpo, Marianne Arnestad, Ritva KarinenAbstract:A sensitive and robust ultra-high-performance liquid chromatography-tandem mass spectrometry method has been developed and validated for the quantification of acetaminophen, Dexchlorpheniramine, caffeine, cotinine and salicylic acid in postmortem blood samples from children younger than 4 years. The sample was prepared by a protein precipitation with ice-cold methanol/acetonitrile mixture (85:15, v/v). The organic phase was evaporated to dryness and the residue was dissolved in the mobile phase. Separation, with gradient elution and an acidic mobile phase, was achieved on an Acquity UPLC® HSS T3 column. The compounds were quantified using a multiple reaction-monitoring mode. Two transitions were monitored for each compound and one for the deuterated internal standards. The mass spectrometric detection in the positive ion mode was performed for all the compounds except salicylic acid which was detected in the negative ionization mode. The limits of quantification were as follows: acetaminophen 0.30 mg/L, Dexchlorpheniramine 0.0050 mg/L, caffeine 0.099 mg/L, cotinine 0.00035 mg/L and salicylic acid 1.3 mg/L. Between-assay and within-assay precisions were ≤15% (biases: -10% to 26%) and ≤10%, respectively. Extraction recoveries varied from 93% to 137%. The matrix effects in blood, corrected with deuterated internal standards, were 100% ± 10% for all compounds except Dexchlorpheniramine (111%) and caffeine (138%).
-
Determination of Acetaminophen, Dexchlorpheniramine, Caffeine, Cotinine and Salicylic acid in 100 μL of Whole Blood by UHPLC-MS/MS.
Journal of analytical toxicology, 2017Co-Authors: Maja Krpo, Marianne Arnestad, Ritva KarinenAbstract:A sensitive and robust ultra-high-performance liquid chromatography-tandem mass spectrometry method has been developed and validated for the quantification of acetaminophen, Dexchlorpheniramine, caffeine, cotinine and salicylic acid in postmortem blood samples from children younger than 4 years. The sample was prepared by a protein precipitation with ice-cold methanol/acetonitrile mixture (85:15, v/v). The organic phase was evaporated to dryness and the residue was dissolved in the mobile phase. Separation, with gradient elution and an acidic mobile phase, was achieved on an Acquity UPLC® HSS T3 column. The compounds were quantified using a multiple reaction-monitoring mode. Two transitions were monitored for each compound and one for the deuterated internal standards. The mass spectrometric detection in the positive ion mode was performed for all the compounds except salicylic acid which was detected in the negative ionization mode. The limits of quantification were as follows: acetaminophen 0.30 mg/L, Dexchlorpheniramine 0.0050 mg/L, caffeine 0.099 mg/L, cotinine 0.00035 mg/L and salicylic acid 1.3 mg/L. Between-assay and within-assay precisions were ≤15% (biases: -10% to 26%) and ≤10%, respectively. Extraction recoveries varied from 93% to 137%. The matrix effects in blood, corrected with deuterated internal standards, were 100% ± 10% for all compounds except Dexchlorpheniramine (111%) and caffeine (138%).
Yvette Michotte - One of the best experts on this subject based on the ideXlab platform.
-
Development of a validated capillary electrophoresis method for enantiomeric purity testing of Dexchlorpheniramine maleate.
Journal of Chromatography A, 2002Co-Authors: Ann Van Eeckhaut, Marc Robert Detaevernier, Yvette MichotteAbstract:Abstract A capillary zone electrophoresis method has been developed for the detection of 0.1% of (R)-levochlorpheniramine maleate in samples of (S)-Dexchlorpheniramine maleate. Using 1.5 mM carboxymethyl-β-cyclodextrin in an acidic background electrolyte, resolution values of more than 10 were obtained. Under these conditions the R-enantiomer is migrating in front of the bulk S-enantiomer. The assay was validated for linearity (2–10 μg/ml; R2=0.9992), selectivity [(RS)-pheniramine maleate and (RS)-brompheniramine maleate], limit of detection (0.25 μg/ml), limit of quantification (0.75 μg/ml), analytical precision (intra- and inter-day variability), repeatability of the method (RSD=5.0%) and accuracy. In samples of Dexchlorpheniramine maleate from two different manufacturers, concentrations of, respectively, 0.15% and 1.95% (m/m) of levochlorpheniramine maleate were detected. The method was compared to the HPLC method described in the European Pharmacopoeia III monograph.
-
Development of a validated capillary electrophoresis method for enantiomeric purity testing of Dexchlorpheniramine maleate.
Journal of Chromatography A, 2002Co-Authors: Ann Van Eeckhaut, Marc Robert Detaevernier, Yvette MichotteAbstract:A capillary zone electrophoresis method has been developed for the detection of 0.1% of (R)-levochlorpheniramine maleate in samples of (S)-Dexchlorpheniramine maleate. Using 1.5 mM carboxymethyl-beta-cyclodextrin in an acidic background electrolyte, resolution values of more than 10 were obtained. Under these conditions the R-enantiomer is migrating in front of the bulk S-enantiomer. The assay was validated for linearity (2-10 microg/ml; R2 = 0.9992), selectivity [(RS)-pheniramine maleate and (RS)-brompheniramine maleate], limit of detection (0.25 microg/ml), limit of quantification (0.75 microg/ml), analytical precision (intra- and inter-day variability), repeatability of the method (RSD = 5.0%) and accuracy. In samples of Dexchlorpheniramine maleate from two different manufacturers, concentrations of, respectively, 0.15% and 1.95% (m/m) of levochlorpheniramine maleate were detected. The method was compared to the HPLC method described in the European Pharmacopoeia III monograph.
Mariele Gobo-oliveira - One of the best experts on this subject based on the ideXlab platform.
-
Gabapentin versus Dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial.
European journal of dermatology : EJD, 2018Co-Authors: Mariele Gobo-oliveira, Vitoria G Pigari, Matheus S. P. Ogata, Hélio Amante Miot, Daniela Ponce, Luciana Pf AbbadeAbstract:Background Uremic pruritus is a common symptom in chronic renal failure patients with undefined pathophysiology. Initial treatment involves topical therapy mainly in the form of moisturizers, however, in many cases, this is not sufficient to relieve itching. Systemic adjuvant therapy is therefore necessary, which commonly includes oral antihistamines, with limited success. Positive effects have been reported for gabapentin. Objectives To evaluate the efficacy and safety of gabapentin vs. Dexchlorpheniramine in reducing uremic pruritus. Materials & methods A randomized, controlled, double-blinded clinical trial for haemodialysis patients with persistent pruritus was performed. Pre-randomisation, cold cream was used for 15 days by 71 participants. Those with pruritus who remained in the study (60 patients) were randomised to receive gabapentin (30 patients; GABA group) or Dexchlorpheniramine (30 patients; DEX group) for 21 days. The primary outcome was the decrease in pruritus score and improvement in quality of life. Results After cold cream use, the participants demonstrated a 37.5% median reduction in Visual Analogue Scale (p 0.7). The median DLQI was reduced from 2 to 1 in the GABA group and from 2 to 0 in the DEX group. Nineteen patients (32%) reported mild/moderate side effects without differences between the groups. Conclusions Uremic pruritus was reduced upon treatment with gabapentin or Dexchlorpheniramine with good safety profiles; no difference was observed between the two treatments.
-
Gabapentin versus Dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
European Journal of Dermatology, 2018Co-Authors: Mariele Gobo-oliveira, Vitoria G Pigari, Matheus S. P. Ogata, Hélio Amante Miot, Daniela Ponce, Luciana Pf AbbadeAbstract:Background Uremic pruritus is acommonsymptom in chronic renal failure patients with undefined pathophysiology. Initial treatment involves topical therapy mainly in the form of moisturizers, however, in many cases, this is not sufficient to relieve itching. Systemic adjuvant therapy is therefore necessary, which commonly includes oral antihistamines, with limited success. Positive effects have been reported for gabapentin. Objectives To evaluate the efficacy and safety of gabapentin vs. Dexchlorpheniramine in reducing uremic pruritus. Materials & Methods A randomized, controlled, double-blinded clinical trial for haemodialysis patients with persistent pruritus was performed. Pre-randomisation, cold cream was used for 15 days by 71 participants. Those with pruritus who remained in the study (60 patients) were randomised to receive gabapentin (30 patients; GABA group) or Dexchlorpheniramine (30 patients;DEXgroup) for 21 days. The primary outcomewas the decrease in pruritus score and improvement in quality of life. Results After cold cream use, the participants demonstrated a 37.5% median reduction in Visual Analogue Scale ( p
Gilberto De Nucci - One of the best experts on this subject based on the ideXlab platform.
-
Anastrozole quantification in human plasma by high-performance liquid chromatography coupled to photospray tandem mass spectrometry applied to pharmacokinetic studies.
Journal of chromatography. B Analytical technologies in the biomedical and life sciences, 2007Co-Authors: Gustavo D Mendes, Daniele Hamamoto, Jaime Ilha, Alberto Dos Santos Pereira, Gilberto De NucciAbstract:A rapid, sensitive and specific method for quantifying the aromatase inhibitor (anastrozole) in human plasma using Dexchlorpheniramine as the internal standard (I.S.) is described herein. The analyte and the I.S. were extracted from 200 microl of human plasma by liquid-liquid extraction using a mixture of diethyl ether:dichloromethane (70:30, v/v) solution. Extracts were removed and dried in the organic phase then reconstituted with 200 microl of acetonitrile:water (50:50; v/v). The extracts were analyzed by high performance liquid chromatography coupled with photospray tandem mass spectrometry (HPLC-MS-MS). Chromatography was performed isocratically on a Genesis, C18 4 microm analytical column (100 mm x 2.1mm i.d.). The method had a chromatographic run time of 2.5 min and a linear calibration curve ranging from 0.05-10 ng ml(-1). The limit of quantification (LOQ) was 0.05 ng ml(-1). This HPLC-MS-MS procedure was used to assess pharmacokinetic studies.